{"id":71278,"date":"2026-07-23T01:22:01","date_gmt":"2026-07-22T23:22:01","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/07\/23\/the-gut-microbiome-drives-endogenous-t-cell-activation-following-car-t-cell-therapy\/"},"modified":"2026-07-23T01:22:01","modified_gmt":"2026-07-22T23:22:01","slug":"the-gut-microbiome-drives-endogenous-t-cell-activation-following-car-t-cell-therapy","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/07\/23\/the-gut-microbiome-drives-endogenous-t-cell-activation-following-car-t-cell-therapy\/","title":{"rendered":"The Gut Microbiome Drives Endogenous T Cell Activation Following CAR-T Cell Therapy"},"content":{"rendered":"<div>\n<p><b>Cancer Immunol Res<\/b>. 2026 Jul 22. doi: 10.1158\/2326-6066.CIR-25-1230. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Chimeric antigen receptor (CAR)-T cell therapy has become a promising clinical approach against hematological malignancies, but patients receiving CAR-T cell therapy still presented inconsistent clinical outcomes and are complicated by incomplete tumor eradication. The gut microbiome has shown strong correlation with the therapeutic outcomes of CAR-T cell therapy. However, the underlying mechanism of how gut microbiota affect CAR-T cell therapeutic potency remained undetermined. In this study, we established a syngeneic CD19+ murine lymphoma model which allows for the evaluation of both endogenous immune cells and gut microbiota following CD19-CD28\u03b6 CAR-T therapy. Using single-cell transcriptomic analyses, we report that CAR-T cell infusion led to the activation of peripheral and gut-infiltrating endogenous CD8+ T cells towards an effector-like phenotype. In parallel, 16S RNA sequencing revealed substantial alterations of gut microbiota post-infusion. The composition of gut bacteria was associated with the activation status of endogenous CD8+ T cells and responsiveness to CAR-T therapy. More specifically, we identified gut bacteria strains Turicibacter and Parvibactor as critical determinants towards effective CAR-T treatment. Supplementation of these species of gut bacteria during CAR-T cell therapy led to superior antitumor efficacy. Furthermore, both strains facilitated CAR-T therapy-induced activation of endogenous CD8+ T cells, enhancing their capability to express activation-associated surface markers as well as tumor-lysis potency. In summary, our results demonstrate that gut microbiome plays an essential role in endogenous immune activation after CAR-T therapy and provide specific targets for therapeutic interventions.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42485357\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=101614637&amp;ff=20260722192200&amp;v=2.20.0\">42485357<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1158\/2326-6066.CIR-25-1230\">10.1158\/2326-6066.CIR-25-1230<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer Immunol Res. 2026 Jul 22. doi: 10.1158\/2326-6066.CIR-25-1230. Online ahead of print. ABSTRACT Chimeric antigen receptor (CAR)-T cell therapy has become a promising clinical approach against hematological malignancies, but patients receiving CAR-T cell therapy still presented inconsistent clinical outcomes and are complicated by incomplete tumor eradication. The gut microbiome has shown strong correlation with the &#8230; <a title=\"The Gut Microbiome Drives Endogenous T Cell Activation Following CAR-T Cell Therapy\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/23\/the-gut-microbiome-drives-endogenous-t-cell-activation-following-car-t-cell-therapy\/\" aria-label=\"Read more about The Gut Microbiome Drives Endogenous T Cell Activation Following CAR-T Cell Therapy\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55,42],"tags":[],"class_list":["post-71278","post","type-post","status-publish","format-standard","hentry","category-cancer-immunology-reserch","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/71278","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=71278"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/71278\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=71278"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=71278"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=71278"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}